Related Experiment Video
Updated: Aug 30, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide
1Department of Endocrinology, Hospital General de Segovia, Madrid, Spain.
Abstract:
Thyrotropin (TSH)-secreting pituitary adenomas are the less frequent form of presentation of pituitary tumors. Selective transsphenoidal surgical resection of the tumor is the treatment of choice. Given that native somatostatin inhibits TSH secretion, treatment with somatostatin analogues has been recently employed in patients with unresectable tumors or after surgery. We report on the case of a 58 year-old man with a TSH-secreting pituitary adenoma who was treated with octreotide for long-term before neurosurgery. The patient was referred to us because of a pituitary mass on CT scanning. Hormonal evaluation resulted in hyperthyroidism with high serum TSH concentrations. Serum alpha subunit concentration was elevated and TSH response to exogenous TRH stimulation was absent. Magnetic resonance imaging of the hypothalamic-pituitary area confirmed the presence of a pituitary mass (2.0 by 1.8 by 1.7 cm). Acutely administered subcutaneous octreotide (100 microg) was followed by a reduction of the serum TSH concentrations. Therefore, the patient received octreotide, 100 microg three times daily for 12 months. At first month after beginning therapy serum TSH, free thyroxine, total triiodothyronine, and alpha subunit concentrations were normalized and persisted into the normal range for the next 11 months. On the other hand, a shrinkage of the tumor mass (1.6 by 1.7 by 1.4 cm) was noted after 6 months of octreotide therapy, however, its volume did not modify in the following next months. Then, the tumor was removed by transsphenoidal surgery and the diagnosis was confirmed by immunohistochemical staining. This case demonstrates that long-term treatment with octreotide gave rise to a normalization of the thyroid function and a reduction of the tumor volume before surgery. This clinical observation suggests that octreotide therapy might be useful in preparation for pituitary surgery in patients with TSH-secreting pituitary adenomas.
Insights
Long-term octreotide treatment normalized thyroid function and reduced tumor size in a patient with a TSH-secreting pituitary adenoma. This suggests octreotide may aid in surgical preparation for such rare pituitary tumors.
Area of Science:
- Endocrinology
- Neurosurgery
- Oncology
Background:
- Thyrotropin (TSH)-secreting pituitary adenomas are rare tumors.
- Surgical resection is the primary treatment, but somatostatin analogues are used for unresectable or post-surgical cases.
Observation:
- A 58-year-old man presented with a TSH-secreting pituitary adenoma causing hyperthyroidism.
- Initial CT revealed a pituitary mass; hormonal evaluation showed elevated TSH and alpha subunit.
- MRI confirmed a 2.0 x 1.8 x 1.7 cm pituitary mass.
Findings:
- Subcutaneous octreotide administration led to reduced TSH levels.
- 12 months of daily octreotide normalized TSH, free thyroxine, total triiodothyronine, and alpha subunit.
- Tumor volume decreased from 2.0 x 1.8 x 1.7 cm to 1.6 x 1.7 x 1.4 cm after 6 months of octreotide therapy.
Implications:
- Long-term octreotide therapy normalized thyroid function and reduced tumor volume pre-surgery.
- Octreotide may be a valuable adjunct in preparing patients with TSH-secreting pituitary adenomas for surgery.
More Related Videos
04:01Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
Published on: September 15, 2023
07:45"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach
Published on: November 28, 2025